CTOs on the Move

Securin Inc.

www.securin.io

 
Securin Inc. is a cybersecurity company based in Albuquerque, New Mexico, founded in 2020. The company focuses on tech-enabled services that help organizations manage cyber risks, reduce attack surfaces, and enhance security postures through predictive intelligence and automation. Securin serves a diverse range of clients globally and is accredited by CREST for Vulnerability Assessment and Penetration Testing (VAPT). The company offers several key services, including Attack Surface Management, Vulnerability Intelligence, Penetration Testing, Vulnerability Management, and Dark Web Monitoring. Securin combines automation with human expertise to provide proactive threat detection and tailored remediation guidance. Its platform is designed to deliver early-warning alerts ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.securin.io
  • 2440 Louisiana Blvd NE
    Albuquerque, NM USA
  • Phone: 505.302.1113

Executives

Name Title Contact Details

Similar Companies

betterwaytech

betterwaytech is a Fitchburg, MA-based company in the Business Services sector.

Henican, James

Henican, James is a Mandeville, LA-based company in the Business Services sector.

Flex People Solutions

Flex People Solutions Inc. is a Toronto, ON-based company in the Business Services sector.

Collective Technologies

Collective Technologies is a Reston, VA-based company in the Business Services sector.

Alkeus Pharmaceuticals, Inc.

Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.